Predictors of thromboxane levels in patients with non-ST-elevation acute coronary syndromes on chronic aspirin therapy

Giampaolo Niccoli; Simona Giubilato; Andrea Leo; Nicola Cosentino; Francesco Fracassi; Leonardo Cataneo; Italo Porto; Antonio Maria Leone; Francesco Burzotta; Carlo Trani; Luigi Marzio Biasucci; Maria Lucia Narducci; Fabio Maria Pulcinelli; Filippo Crea

doi:10.1160/TH11-09-0635

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2012; 108(01): 133-139
DOI: 10.1160/TH11-09-0635

Wound Healing and Inflammation / Infection

Schattauer GmbH

Predictors of thromboxane levels in patients with non-ST-elevation acute coronary syndromes on chronic aspirin therapy

Authors

Giampaolo Niccoli

¹Institute of Cardiology, Catholic University, Rome, Italy
Simona Giubilato

¹Institute of Cardiology, Catholic University, Rome, Italy
Andrea Leo

¹Institute of Cardiology, Catholic University, Rome, Italy
Nicola Cosentino

¹Institute of Cardiology, Catholic University, Rome, Italy
Francesco Fracassi

¹Institute of Cardiology, Catholic University, Rome, Italy
Leonardo Cataneo

¹Institute of Cardiology, Catholic University, Rome, Italy
Italo Porto

¹Institute of Cardiology, Catholic University, Rome, Italy
Antonio Maria Leone

¹Institute of Cardiology, Catholic University, Rome, Italy
Francesco Burzotta

¹Institute of Cardiology, Catholic University, Rome, Italy
Carlo Trani

¹Institute of Cardiology, Catholic University, Rome, Italy
Luigi Marzio Biasucci

¹Institute of Cardiology, Catholic University, Rome, Italy
Maria Lucia Narducci

¹Institute of Cardiology, Catholic University, Rome, Italy
Fabio Maria Pulcinelli

²Department of Experimental Medicine, “Sapienza” University of Rome, Italy
Filippo Crea

¹Institute of Cardiology, Catholic University, Rome, Italy

Abstract

Summary

High levels of thromboxane A2 (TxA2), a key mediator of platelet activation and aggregation, are associated with an increased risk of cardiovascular events. We aimed at assessing the predictors of higher plasma levels of TxB2, the stable metabolite of TxA2, in consecutive patients presenting with non-ST-elevation acute coronary syndrome (NSTE-ACS) on previous aspirin (ASA) treatment undergoing coronary angiography. Ninety-eight consecutive patients (age 61 ± 11, 75% males) with NSTE-ACS, on previous chronic ASA treatment, were prospectively enrolled in this study. Coronary disease extent was assessed by angiography according to the Bogaty score. In all patients, admission plasma levels of TxB2 (pg/ml) were measured by enzyme-linked immunosorbent assay, and patients showing TxB2 levels in the fourth quartile were compared to patients showing TxB2 levels in the lower quartiles. Multivariable logistic regression analysis showed that platelet count (odds ratio [OR] 1.18, 95% confidence interval [CI] 1.02–1.63, p=0.04), multivessel coronary disease (OR 1.37, 95% CI 1.13–3.67, p=0.03), and coronary atherosclerosis extent index (OR 1.91, 95% CI 1.45–6.79, p=0.001) were independent predictors of TxB2 level upper quartile. Of note, C-reactive protein serum levels were similar in patients with TxB2 levels in the upper quartile as compared to those in the lower quartiles (p=0.49). In conclusion, NSTE-ACS patients with severe coronary atherosclerosis may have incomplete suppression of TxA2 production despite chronic ASA therapy. This finding suggests that additional efforts should be made to lower TxA2 levels in patients with widespread coronary artery disease.

Keywords

Thromboxane A2 - aspirin - coronary atherosclerosis - non-ST-elevation acute coronary syndromes

Volltext

Referenzen

References
1 The Second International Study of Infarct Survival Collaborative Group. Randomized trial of intravenous streptokinase,oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 02: 349-360.
2 Antithrombotic Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy—II: maintenance of vascular graft or arterial patency by antiplatelet therapy. Br Med J 1994; 308: 159-168.
3 Baigent C, Suldow C, Collins R. et al. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324: 71-86.
4 Patrono C, Garcìa Rodrìguez LA, Landolfi R. et al. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353: 2373-2383.
5 Michelson AD, Cattaneo M, Eikelboom JW. et al. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost 2005; 03: 1309-1311.
6 Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet 2006; 367: 606-617.
7 Wang TH, Bhatt DL, Topol EJ. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J 2006; 27: 647-654.
8 Michos ED, Ardehali R, Blumenthal RS. et al. Aspirin and clopidogrel resistance. Mayo Clinic 2006; 81: 518-526.
9 Snoep JD, Hovens MMC, Eikenboom JCJ. et al. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events. A systematic review and meta-analysis. Arch Intern Med 2007; 167: 1593-1599.
10 Krasopoulos G, Brister SJ, Beattie WS. et al. Aspirin ‘‘resistance’’ and risk of cardiovascular morbidity: systematic review and meta-analysis. Br Med J 2008; 336: 195-198.
11 Cresente M, Di Castalnuovo A, Iacoviello L. et al. PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a metaanalysis of 19 studies comprising 3,003 patients. Thromb Haemost 2008; 99: 1129-1131.
12 Pulcinelli FM, Riondino S, Celestini A. et al. Persistent production of platelet thromboxane A2 in patients chronically treated with aspirin. J Thromb Haemost 2005; 03: 2784-2789.
13 Sciulli MG, Renda G, Capone ML. et al. Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease. Clin Pharmacol Ther 2006; 80: 115-125.
14 Reilly IA, Fitzgerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 1987; 180-186.
15 Eikelboom JW, Hirsh J, Weitz JI. et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 1650-1655.
16 Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007; 357: 2482-2494.
17 Gawaz M, Stellos K, Langer HF. Platelets modulate atherogenesis and progression of atherosclerotic plaques via interaction with progenitor and dendritic cells. J Thromb Haemost 2008; 06: 235-242.
18 Fitzgerald DJ, Roy L, Catella F, Fet al. Platelet activation in unstable coronary disease. N Engl J Med 1986; 315: 983-989.
19 Brydon L, Magid K, Steptoe A. Platelets, coronary heart disease, and stress. Brain Behav Immun 2006; 20: 113-119.
20 Nicholls SJ, Tuzcu EM, Crowe T. et al. Relationship between cardiovascular risk factors and atherosclerotic disease burden measured by intravascular ultrasound. J Am Coll Cardiol 2006; 47: 1967-1975.
21 Cerletti C, Dell’Elba G, Manarini S. et al. Pharmacokinetic and pharmacodynamic differences between two low dosages of aspirin may affect therapeutic outcomes. Clin Pharmacokinet 2003; 42: 1059-1070.
22 Riondino S, Trifirò E, Principessa L. et al. Lack of biological relevance of platelet cyclooxygenase-2 dependent thromboxane 2 production. Thromb Res 2008; 122: 359-365.
23 Morrow DA, Antman EM, Charlesworth A. et al. TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation. Circulation 2000; 102: 2031-2037.
24 Bogaty P, Brecker SJ, White SE. et al. Comparison of coronary angiographic findings in acute and chronic 1st presentation of ischemic-heart-disease. Circulation 1993; 87: 1938-1946.
25 Starlinger P, Moll HP, Assinger A. et al. Thrombospondin-1: a unique marker to identify in vitro platelet activation when monitoring in vivo processes. J Thromb Haemost 2010; 08: 1809-1819.
26 Eikelboom JW, Hankey GJ, Thom J. et al. On behalf of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) Investigators. Incomplete Inhibition of Thromboxane Biosynthesis by Acetylsalicylic Acid Determinants and Effect on Cardiovascular Risk. Circulation 2008; 118: 1705-1712.
27 Catella F, Healy D, Lawson J. et al. 11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation. Proc Natl Acad Sci USA 1986; 83: 5861-5865.
28 Rasoul S, Ottervanger JP, de Boer MJ. et al. A comparison of dual vs. triple antiplatelet therapy in patients with non-ST-segment elevation acute coronary syndrome: results of the ELISA-2 trial. Eur Heart J 2006; 27: 1401-1407.
29 Breeman A, Mercado N, Lenzen M. et al. Characteristics, treatment and outcome of patients with non-ST-elevation acute coronary syndromes and multivessel coronary artery disease: observations from PURSUIT (platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrelin therapy). Cardiology 2002; 98: 195-201.
30 Belton O, Byrne D, Kearney D. et al. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 2000; 102: 840-845.
31 Pundziute G, Schuijf JD, Jukema JW. et al. Advances in the noninvasive evaluation of coronary artery disease with multislice computed tomography. Expert Rev Med Devices 2006; 03: 441-451.
32 Mehta SR, Tanguay JF, Eikelboom JW. et al. CURRENT-OASIS 7 trial investigators. Double-dose versus standard-dose clopidogrel and high-dose versus lowdose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 2010; 376: 1233-1243.
33 Furman MI, Benoit SE, Barnard MR. et al. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol 1998; 31: 352-358.
34 Keating FK, Whitaker DA, Kabbani SS. et al. Relation of augmented platelet reactivity to the magnitude of distribution of atherosclerosis. Am J Cardiol 2004; 94: 725-728.
35 Sanioglu S, Tetik S, Sokullu O. et al. Aspirin resistance after CABG. Thorac Cardiovasc Surg 2009; 57: 281-285.
36 Zimmermann N, Kurt M, Winter J. et al. Detection and duration of aspirin resistance after coronary artery bypass grafting. J Thorac Cardiovasc Surg 2008; 135: 947-948.
37 Hobikoglu GF, Norgaz T, Aksu H. et al. The effect of acetylsalicylic acid resistance on prognosis of patients who have developed acute coronary syndrome during acetylsalicylic acid therapy. Can J Cardiol 2007; 23: 201-206.
38 Kidson-Gerber G, Weaver J, Gemmell R. et al. Serum thromboxane B2 compared to five other platelet function tests for the evaluation of aspirin effect in stable cardiovascular disease. Heart Lung Circ 2010; 19: 234-242.
39 Muir AR, McMullin MF, Patterson C. et al. Assessment of aspirin resistance varies on a temporal basis in patients with ischaemic heart disease. Heart 2009; 95: 1225-1229.
40 Jouve R, Rolland PH, Delboy C. et al. Thromboxane B2, 6-keto-PGF1 alpha, PGE2, PGF2 alpha, and PGA1 plasma levels in arteriosclerosis obliterans: relationship to clinical manifestations, risk factors, and arterial pathoanatomy. Am Heart J 1984; 107: 45-52.
41 Schonbeck U, Sukkova GK, Graber P. et al. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol 1999; 155: 1281-1291.
42 Maclouf J, Folco G, Patrono C. Eicosanoids and iso-eicosanoids: constitutive, inducible and transcellular biosynthesis in vascular disease. Thromb Haemost 1998; 79: 691-705.
43 Rocca B, Secchiero P, Ciabattoni G. et al. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci USA 2002; 99: 7634-7639.
44 Lordkipanidzé M. Why an aspirin a day no longer keeps the doctor away …. Thromb Haemost 2011; 105: 209-210.
45 Perneby C, Wallen HN, Rooney C. et al. Dose- and time-dependent antiplatelet effects of aspirin. Thromb Haemost 2006; 95: 652-658.
46 Brown AS, Martin JF. The megakaryocyte platelet system and vascular disease. Eur J Clin Invest 1994; 24 (Suppl. 01) 9-15.
47 Ault KA, Rinder HM, Mitchell J. et al. The significance of platelets with increased RNA content (reticulated platelets). A measure of the rate of thrombopoiesis. Am J Clin Pathol 1992; 98: 637-646.
48 Guthikonda S, Lev EI, Patel R. et al. Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. J Thromb Haemost 2007; 05: 490-496.
49 Kieffer N, Guichard J, Farcet JP. et al. Biosynthesis of major platelet proteins in human blood platelets. Eur J Biochem 1987; 164: 189-195.
50 Grove EL, Hvas AM, Mortensen SB. et al. Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease. J Thromb Haemost 2011; 09: 185-191.
51 Grove EL, Hvas AM, Kristensen SD. Immature platelets in patients with acute coronary syndromes. Thromb Haemost 2009; 101: 151-156.
52 Ly HQ, Kirtane AJ, Murphy SA. et al. Association of platelets counts on presentation and clinical outcomes in ST-elevation myocardial infarction (from the TIMI Trials). Am J Cardiol 2006; 98: 1-5.
53 Bath PM, Butterworth RJ. Platelet size: measurement, physiology and vascular disease. Blood Coagul Fibrinolysis 1996; 07: 157-161.
54 Santos M, Fuset M, Ruano M. et al. Effect of atorvastatin on platelet thromboxane A(2) synthesis in aspirin-treated patients with acute myocardial infarction. Am J Cardiol 2009; 104: 1618-1623.
55 Tirnaksiz E, Pamukcu B, Oflaz H. et al. Effect of high dose statin therapy on platelet function; statins reduce aspirin-resistant platelet aggregation in patients with coronary heart disease. J Thromb Thrombolysis 2009; 27: 24-28.
56 Würtz M, Grove EL, Kristensen SD. et al. The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease. Heart 2010; 96: 368-371.
57 Santilli F, Rocca B, De Cristofaro R. et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin ″resistance″. J Am Coll Cardiol 2009; 53: 667-677.